Clinical trial: pilot study of metformin for the treatment of non‐alcoholic steatohepatitis

Background  Non‐alcoholic steatohepatitis (NASH) is a form of progressive fatty liver disease that is strongly associated with insulin resistance, which suggests that insulin sensitizing agents such as metformin may be beneficial for NASH.

[1]  D. Kleiner,et al.  Placebo in nonalcoholic steatohepatitis: insight into natural history and implications for future clinical trials. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[3]  T. Harris,et al.  Lipin 1 is an inducible amplifier of the hepatic PGC-1α/PPARα regulatory pathway , 2006 .

[4]  M. Febbraio,et al.  CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK , 2006, Nature Medicine.

[5]  T. Harris,et al.  Lipin 1 is an inducible amplifier of the hepatic PGC-1alpha/PPARalpha regulatory pathway. , 2006, Cell metabolism.

[6]  S. Sanderson,et al.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.

[7]  F. Anania,et al.  The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. , 2005, The American journal of pathology.

[8]  G. Marchesini,et al.  A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease , 2005, The American Journal of Gastroenterology.

[9]  R. Deutsch,et al.  A phase 2 clinical trial of metformin as a treatment for non‐diabetic paediatric non‐alcoholic steatohepatitis , 2005, Alimentary pharmacology & therapeutics.

[10]  J. Clore,et al.  A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  G. Farr,et al.  Metformin in the treatment of non‐alcoholic steatohepatitis: a pilot open label trial , 2004, Alimentary pharmacology & therapeutics.

[12]  L. Burgart,et al.  Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial , 2004, Hepatology.

[13]  J. Hoofnagle,et al.  A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis , 2004, Hepatology.

[14]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[15]  B. Neuschwander‐Tetri,et al.  Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR‐γ ligand rosiglitazone , 2003, Hepatology.

[16]  H. Cortez‐Pinto,et al.  Erratum: Nonalcoholic steatohepatitis: Summary of an AASLD single topic conference (Hepatology (2003) 37 (1202-1219)) , 2003 .

[17]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference , 2003, Hepatology.

[18]  Peter J Moate,et al.  MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. , 2003, Diabetes technology & therapeutics.

[19]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[20]  J. P. Kay,et al.  Beneficial effects of metformin in normoglycemic morbidly obese adolescents. , 2001, Metabolism: clinical and experimental.

[21]  S. Caldwell,et al.  A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis , 2001, American Journal of Gastroenterology.

[22]  F. Kuhajda,et al.  Metformin reverses fatty liver disease in obese, leptin-deficient mice , 2000, Nature Medicine.

[23]  S Fiorini,et al.  Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. , 2000, The Journal of clinical endocrinology and metabolism.

[24]  Jay D. Horton,et al.  Increased Levels of Nuclear SREBP-1c Associated with Fatty Livers in Two Mouse Models of Diabetes Mellitus* , 1999, The Journal of Biological Chemistry.

[25]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[26]  C. Day,et al.  Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. , 1998, Journal of hepatology.

[27]  J. Ludwig,et al.  Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. , 1980, Mayo Clinic proceedings.